Novel Therapeutic Strategy for Renal Cell Carcinoma: Niclosamide Enhances Sunitinib Efficacy via DNA Repair and Cell Cycle Pathways
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262210922 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ae Ryang Jung und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Niclosamide, DNA Repair, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT), Catholic Medical Center Research Foundation, National Research Foundation of Kore.
Abstract (Originalsprache)
Tyrosine kinase inhibitors (TKIs), such as sunitinib and sorafenib, are standard treatments for renal cell carcinoma (RCC). However, most patients treated with these drugs eventually develop drug resistance and relapse; therefore, new treatment options for RCC are urgently required. Recent studies have focused on combination therapies targeting distinct molecular pathways that may produce synergistic effects and help overcome drug resistance in RCC. Niclosamide, an anthelmintic agent, is effective against various cancers; however, its potential in combination with sunitinib for treating RCC has not been evaluated. In this study, we assessed the therapeutic efficacy of niclosamide in combination with sunitinib against RCC and explored the underlying molecular mechanisms. Niclosamide alone inhibited RCC cell proliferation, whereas its combination with sunitinib produced a synergistic anticancer effect, both in vitro and in vivo. RNA sequencing (RNA-seq) and bioinformatic analyses showed that niclosamide modulated critical pathways, including BRIP1- and FANCA-mediated DNA repair and E2F2-regulated cell cycle progression. These findings provide proof-of-concept that niclosamide enhances TKI efficacy through modulation of DNA repair and cell cycle pathways, supporting the rationale for DNA damage response (DDR)-targeted combination strategies in RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
ORCID-Profile: Dongho Shin, Ji Youl Lee, Yong Hyun Park
Förderung
- National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT)
- Catholic Medical Center Research Foundation
- National Research Foundation of Kore
Zitieren
APA
Jung, A. R., Kim, G. E., Kim, M. Y., Rhew, S. A., Shin, D., Ha, U. S., Hong, S. H., Lee, J. Y., Kim, S. W., & Park, Y. H. (2025). Novel Therapeutic Strategy for Renal Cell Carcinoma: Niclosamide Enhances Sunitinib Efficacy via DNA Repair and Cell Cycle Pathways. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262210922
Vancouver
Jung AR, Kim GE, Kim MY, Rhew SA, Shin D, Ha US, et al. Novel Therapeutic Strategy for Renal Cell Carcinoma: Niclosamide Enhances Sunitinib Efficacy via DNA Repair and Cell Cycle Pathways. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262210922
BibTeX
@article{Jung2025,
author = {Jung, Ae Ryang and Kim, Ga Eun and Kim, Mee Young and Rhew, Seung Ah and Shin, Dongho and Ha, U-Syn and Hong, Sung-Hoo and Lee, Ji Youl and Kim, Sae Woong and Park, Yong Hyun},
title = {Novel Therapeutic Strategy for Renal Cell Carcinoma: Niclosamide Enhances Sunitinib Efficacy via DNA Repair and Cell Cycle Pathways},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262210922}
}
EUVIMED